1. Methylation marks in blood DNA reveal breast cancer risk in patients fulfilling hereditary disease criteria
- Author
-
Miguel Ruiz-De La Cruz, Héctor Martínez-Gregorio, Clara Estela Díaz-Velásquez, Fernando Ambriz-Barrera, Norma Gabriela Resendiz-Flores, Rina Gitler-Weingarten, María Patricia Rojo-Castillo, Didier Pradda, Javier Oliver, Sandra Perdomo, Eva María Gómez-García, Aldo Hugo De La Cruz-Montoya, Luis Ignacio Terrazas, Gabriela Torres-Mejía, Fidel de la Cruz Hernández-Hernández, and Felipe Vaca-Paniagua
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Less than 15–20% of patients who meet the criteria for hereditary breast and ovarian cancer (HBOC) carry pathogenic coding genetic mutations, implying that other molecular mechanisms may contribute to the increased risk of this condition. DNA methylation in peripheral blood has been suggested as a potential epigenetic marker for the risk of breast cancer (BC). We aimed to discover methylation marks in peripheral blood associated with BC in 231 pre-treatment BC patients meeting HBOC criteria, testing negative for coding pathogenic variants, and 156 healthy controls, through methylation analysis by targeted bisulfite sequencing on 18 tumor suppressor gene promoters (330 CpG sites). We found i) hypermethylation in EPCAM (17 CpG sites; p = 0.017) and RAD51C (27 CpG sites; p = 0.048); ii) hypermethylation in 36 CpG-specific sites (FDR q
- Published
- 2024
- Full Text
- View/download PDF